Cytosorbents (CTSO) Net Cash Flow Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -54.17% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | 64.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.90% |
| Mar 31, 2026 | -136.41% |
| Dec 31, 2025 | -14.80% |
| Sep 30, 2025 | 11.85% |
| Jun 30, 2025 | -133.34% |
| Mar 31, 2025 | 160.02% |
| Dec 31, 2024 | -140.55% |
| Sep 30, 2024 | 40.59% |
| Jun 30, 2024 | 183.96% |
| Mar 31, 2024 | -77.95% |
| Dec 31, 2023 | 1,137.17% |
| Sep 30, 2023 | 35.37% |
| Jun 30, 2023 | 53.93% |
| Mar 31, 2023 | 65.51% |
| Dec 31, 2022 | 92.46% |
| Sep 30, 2022 | -63.36% |
| Jun 30, 2022 | -340.15% |
| Mar 31, 2022 | -213.41% |
| Dec 31, 2021 | 56.01% |
| Sep 30, 2021 | -108.66% |